Amorfix Antibody Development Program for ALS to be Presented at Leading ALS Conference

Amorfix Antibody Development Program for ALS to be Presented at Leading ALS 
Conference 
TSX: AMF 
TORONTO, Nov. 1, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
Dr. Neil Cashman, Amorfix Chief Scientific Officer and Company founder, is a 
lead presenter at today's 8(th )Annual ALS Therapy Development Institute's 
Leadership Summit being held in Boston, MA. He is providing a 
state-of-the-art overview of Amorfix's therapeutic SOD1 antibody program for 
the treatment of ALS. 
Amorfix is a leader in ALS research and is committed to developing novel 
diagnostics and therapeutics for ALS. The Company has identified antibody 
targets against misfolded SOD1 for the treatment of ALS which have been 
licensed to Biogen Idec for the development of antibody therapeutics, and to 
Pan Provincial Vaccine Enterprise (PREVENT) for the development of vaccine 
applications. Both of these programs are advancing in preclinical 
development. In addition, the Company is developing a blood test to be used 
as a diagnostic tool for the early detection of ALS, based on the detection 
and measurement of misfolded SOD1 present in plasma. 
About ALS
Amyotrophic lateral sclerosis, ALS or Lou Gehrig's disease,is a fatal 
neurodegenerative disease. People living with the disease become progressively 
paralyzed due to degeneration of the upper and lower motor neurons in the 
brain and spinal cord. Eighty per cent of people with ALS die within two to 
five years of diagnosis; unable to breathe or swallow. Ten per cent of those 
affected may live for 10 years or longer 
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
a cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD) and 
mild cognitive impairment (MCI), and an ultrasensitive method for detecting 
the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood 
from animal models of AD. For more information about Amorfix, visit 
www.amorfix.com. 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. 
This news release contains certain forward-looking information, which involves 
known and unknown risks, uncertainties and other factors that may cause actual 
results, performance or achievements to be materially different from those 
implied by statements herein, and therefore these statements should not be 
read as guarantees of future performance or results. All forward-looking 
statements are based on the Company's current beliefs as well as assumptions 
made by and information currently available to it, such as the commitments of 
potential subscribers that are not binding legal obligations, as well as other 
factors, that are subject to change. Readers are cautioned not to place 
undue reliance on these forward-looking statements, which speak only as of the 
date of this press release. Due to risks and uncertainties, including the 
risks and uncertainties identified by the Company in its public securities 
filings, actual events may differ materially from current expectations. The 
Company disclaims any intention or obligation to update or revise any 
forward-looking statements, whether as a result of new information, future 
events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Please contact: 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com 
Janet Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 
847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com 
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2012/01/c3937.html 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC 2575 WNEWS  
-0- Nov/01/2012 11:20 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.